CureVac N.V. (NASDAQ:CVAC) shares, rose in value on Thursday, April 04, with the stock price up by 1.37% to the previous day’s close as strong demand from buyers drove the stock to $2.95.
Actively observing the price movement in the recent trading, the stock is buoying the session at $2.91. The value of beta (5-year monthly) is 2.53. Referring to stock’s 52-week performance, its high was $12.36, and the low was $2.76. On the whole, CVAC has fluctuated by -11.41% over the past month.
With the market capitalization of CureVac N.V. currently standing at about $660.45 million, investors are eagerly awaiting this quarter’s results, scheduled for Apr 23, 2024 – Apr 29, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.2, which is expected to increase to -$0.15 for fiscal year -$1.03 and then to about -$0.98 by fiscal year 2024. Data indicates that the EPS growth is expected to be 29.00% in 2024, while the next year’s EPS growth is forecast to be 4.90%.
Analysts have estimated the company’s revenue for the quarter at $36.33 million, with a low estimate of $20.23 million and a high estimate of $77.53 million. According to the average forecast, sales growth in current quarter could jump up 183.10%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2024, the company’s y-o-y revenues would reach $59.7 million, representing a decrease of -19.20% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that CVAC’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of CVAC currently trading nearly -6.41% and -12.11% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 38.46, while the 7-day volatility ratio is showing 4.63% which for the 30-day chart, stands at 5.44%. Furthermore, CureVac N.V. (CVAC)’s beta value is 2.50, and its average true range (ATR) is 0.17.
A comparison of CureVac N.V. (CVAC) with its peers suggests the former has fared considerably weaker in the market. CVAC showed an intraday change of 1.37% in today’s session so far, and over the past year, it shrunk by -58.51%%.
Data on historical trading for CureVac N.V. (NASDAQ:CVAC) indicates that the trading volumes over the past 10 days have averaged 0.56 million and over the past 3 months, they’ve averaged 783.19K. According to company’s latest data on outstanding shares, there are 223.88 million shares outstanding.
Nearly 59.08% of CureVac N.V.’s shares belong to company insiders and institutional investors own 10.02% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.86 million shares as on Mar 15, 2024, resulting in a short ratio of 6.2. According to the data, the short interest in CureVac N.V. (CVAC) stood at 2.17% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 4.26 million. The stock has fallen by -29.93% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CVAC stock heading into the next quarter.
